Loading...
Market
What market share will Merck's CN201 therapy achieve in the B-cell malignancies treatment market by December 31, 2025?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Market research reports and industry analyses
Story
Merck Acquires CN201 Therapy for $1.3 Billion
Aug 9, 2024, 12:11 PM
Merck has announced its acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical. The deal involves an upfront payment of $700 million in cash, with potential earnouts of up to $600 million, bringing the total transaction value to $1.3 billion. CN201 is a next-generation CD3xCD19 bispecific antibody that aims to enhance Merck’s pipeline with potential applications in treating B-cell malignancies and autoimmune diseases. This strategic acquisition highlights Merck's commitment to expanding its capabilities in immune disease therapeutics.
View original story
Similar markets
Less than $100M • 25%
$100M - $500M • 25%
$500M - $1B • 25%
More than $1B • 25%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
B-cell malignancies • 25%
Autoimmune diseases • 25%
Both • 25%
Neither • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%